While influential heavy weight attendees ( only 1 of the 4Ps )...

While influential heavy weight attendees ( only 1 of the 4Ps ) are important but more importantly Imugene 2024 is quite different from 2023. We now have 5 different platforms with several Phase1, 1b, 2, and 2b clinical trials running concurrently as mono mon toxic or combo therapies.

A couple of exciting examples briefly:

1) the amazing FDA Fast Track Designation approval on 28/11/2023 for our CF33 Vaxinia due to 86% Response Rate 1 Complete. Response and 1 Stable Disease for 1 year and 6 months respectively for late stage Bile cancer patients (despite at very dose ..… isn’t it incredible). No need being a rocket genius like like Elon, just imagine the immense implication here.

2) Then, Azer Cel Registration Trial is being organised for relapsed autogenic CarT blood cancer patients. and the potential combo trial with another holy grail onCARlytics cf33-cd19 which itself has very recently dosed the 1st patient as a mono therapy to begin with.

man I’m excited

As such , IMO, Imugene 2024 is seriously at an inflection point here. We are at the right place, at the right time, with the right products , and the right people. The 4Ps and SWOT are absolutely aligned in our favour….

There is no other better venture or event than JP Morgan Health Conference 8-11 Jan 2024 California. Biden is “sending” his Director for his Moonshot Cancer Project as a Panelist and as keynote speaker. This speaks huge volume. Whether we will get an imminent PS announcement or not isn’t important but this Conference will undeniably set the right tone for potential deals/ commercialise partnerships . Well, I’m tightening my seatbelt for G force.

GL patients n investors
Kluck

ps. No proof reading. Typing on iPhone 5. Left the 13 elsewhere while Caring for 2 old dogs. ciao